In this solo episode, host Dr. Keisha Davis, a triple board-certified pathologist, breaks down how cancers are diagnosed — and why things aren’t always as straightforward as they seem.

With headlines swirling around President Biden’s prostate cancer diagnosis, Dr. Davis brings clarity to what Gleason scores actually mean, the difference between cancer grading and staging, and how a patient’s outcome depends not just on biology but also on access, screening guidelines, and physician discretion.

She takes listeners inside the world of pathology — explaining how cancers are caught (or missed) through tissue biopsies, tumor markers, imaging, and more. From prostate cancer to soft tissue tumors to blood cancers, this episode is a crash course in understanding the nuance behind every lab report.

Plus: Updates on FDA policy shifts, COVID vaccine guidance, and the status of bird flu testing.

Host Dr. Keisha Davis, M.D.
Triple board-certified pathologist & fitness professional
https://drkeishadavis.komi.io

News Updates Covered in This Episode:

• Biden’s prostate cancer: Gleason score confusion and metastatic risk in older men

• FDA will not recommend updated COVID vaccine formulation for fall 2025

• Delays in bird flu reporting and testing protocols raise concerns

• Latest product recalls including eye care and food contamination

Resources Mentioned:

• Cancer screening guidelines: https://www.cancer.gov/about-cancer/screening

• FDA recalls database: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

• CDC cancer basics: https://www.cdc.gov/cancer/dcpc/about/

Subscribe to The Medical Collective Podcast https://themedicalcollective.komi.io